Dr. Schwartz is a highly experienced biotechnology CEO, serving as adviser to several biotechnology and medical device companies including Theracaine, Neolight, and bioSyntagma. He holds adjunct faculty positions at San Jose State University with appointments in the Masters in Biotechnology Program, the Lucas School of Management in the Business College, and the department of Biology. Dr. Schwartz has extensive experience in managing, funding, and growing startup ventures as well as public biotechnology companies, including fund raising, executing strategic transactions, strategic planning, business development/M&A, clinical and product development. He has experience in conducting business on a worldwide basis, working with corporate, academic and non-profit partners. He has held senior management, research and board positions in multiple life science industries including therapeutics, diagnostics, and research products. He served on the board of directors for the Biotechnology Industry Association, as well as an advisor for CalBio, and is currently on the advisory board of CEI in Phoenix. Located in the Bay Area, Dr. Schwartz has deep contacts in both the biotech industry and the financial community. Dr. Schwartz’s leadership has resulted in significant corporate developments including the growth and maturation of early stage startups as well as liquidity events and returns to shareholders in numerous companies.